Business Context and Reporting Period
This Form 6-K is a transaction notification filed by GlaxoSmithKline plc for the period ending August 9, 2016. The filing reports a specific transaction involving a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR) of the company.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a single securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the acquisition of 1 American Depositary Share (ADS) by Dr. K. Slaoui (PCA of Dr. M. M. Slaoui, Chairman, Global Vaccines).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed on August 8, 2016, at a price of $44.41 per ADS, resulting from the revaluation of the cash element of a notional investment within the GSK 401(K) plan.
Investor Verification Points
- Verify the identity of the PCA (Dr. K. Slaoui) and their relationship to the PDMR (Dr. M. M. Slaoui).
- Confirm the transaction date (August 8, 2016) and price ($44.41) against market data for GSK ADSs.
- Note that this filing does not reflect broader company performance or strategic shifts.